Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19-Reference-Cited by-同舟云学术

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

Published:2020-06 Issue: Volume:41 Page:102135
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Giovannoni Gavin

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference8 articles.

1. ABN Guidance on the Use of Disease-Modifying Therapies in Multiple Sclerosis in Response to the Threat of a Coronavirus Epidemic [WWW Document],2020

2. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis;Hauser;N. Engl. J. Med.,2017

3. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized opera I, opera II, and oratorio studies;Mayer;Mult. Scler. Relat. Disord.,2019

4. Ocrelizumab versus placebo in primary progressive multiple sclerosis;Montalban;N. Engl. J. Med.,2017

5. Fulminant hepatitis associated with echovirus 25 during treatment with ocrelizumab for multiple sclerosis;Nicolini;JAMA Neurol.,2019

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience;Current Neuropharmacology;2024-02

2. Outcomes of COVID-19 disease and its effect on disability in patients with multiple sclerosis and other allied demyelinating disorders;Clinical Neurology and Neurosurgery;2024-02

3. The course of COVID-19 in a multiple sclerosis: a case report;Wiadomości Lekarskie;2024-01

4. A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder;Current Neurology and Neuroscience Reports;2023-08-04

5. Therapeutics for the Management of Cytokine Release Syndrome in COVID-19;Current Topics in Medicinal Chemistry;2023-01